Summary

The Global Wildlife Health Market is valued at approximately USD 2.3 billion in 2023 and is anticipated to grow with a steady yet significant compound annual growth rate of 8.90% over the forecast period 2024–2032. The intersection of biodiversity conservation, global zoonotic disease surveillance, and ecological sustainability is driving heightened awareness around wildlife health management. As ecosystems face mounting threats from urbanization, climate change, and infectious disease outbreaks, stakeholders across governments, research institutions, NGOs, and veterinary science communities are mobilizing efforts to safeguard wild animal populations. This has led to an escalating demand for integrated health solutions—including pharmaceuticals, medical diagnostics, and field-deployable veterinary services—that can address the health complexities of diverse wildlife species ranging from mammals and birds to amphibians and reptiles.
The ongoing shift toward a One Health framework—recognizing the interconnectedness of animal, human, and environmental health—has become a key catalyst for growth in this market. The emergence and re-emergence of zoonotic pathogens such as avian influenza, SARS-CoV-2, and anthrax in wildlife reservoirs have underlined the urgent need for early detection, robust immunization strategies, and responsive care infrastructures. As such, investments are being funneled into advanced diagnostics, cold-chain enabled vaccine development, portable treatment kits, and AI-enabled wildlife surveillance systems. Furthermore, pharmaceutical innovations targeting species-specific disease profiles are gaining traction, along with improved biosecurity protocols that help monitor and manage the health of wild populations both in situ and in controlled habitats.
Simultaneously, the integration of smart technologies and GIS-based tracking into wildlife health monitoring is enabling field veterinarians and conservationists to achieve unprecedented precision in identifying outbreaks, tracking migration-related stress, and administering therapeutic interventions. Medical devices designed for non-invasive diagnostics, remote imaging, and rapid field testing are also revolutionizing the manner in which health evaluations are conducted in remote, often challenging, ecological environments. Alongside this technological evolution, partnerships between conservation bodies and veterinary pharmaceutical firms are expanding, with tailored solutions being co-developed for high-risk ecosystems such as wetlands, marine zones, and tropical forests.
Regionally, North America commands a significant share of the global wildlife health market, primarily due to its robust wildlife conservation frameworks, strong veterinary infrastructure, and governmental funding programs. Europe, supported by stringent wildlife health regulations and biodiversity strategies, is not far behind. However, Asia Pacific is poised to register the fastest growth during the forecast period. The region’s rich biodiversity, combined with increasing human-wildlife interaction and rising government involvement in zoonosis mitigation, is catalyzing demand for wildlife health interventions. Latin America and Africa, while still emerging, offer untapped opportunities as local ecosystems face mounting pressures and international collaboration increases.
Major market player included in this report are:
• Zoetis Inc.
• Merck & Co., Inc.
• Virbac
• Boehringer Ingelheim International GmbH
• Ceva Santé Animale
• Elanco Animal Health Incorporated
• IDEXX Laboratories, Inc.
• Vetoquinol SA
• Thermo Fisher Scientific Inc.
• Biovet S.A.
• Hester Biosciences Limited
• Phibro Animal Health Corporation
• Indian Immunologicals Ltd
• Neogen Corporation
• Bimeda Inc.
The detailed segments and sub-segment of the market are explained below:
By Species
• Mammals
• Birds
• Fish
• Reptiles
• Amphibians
By Products & Services
Pharmaceuticals
• Drugs
• Vaccines
Medical Devices
• Diagnostics Equipment
• Consumables
Veterinary Services
By End-user
• Government & Wildlife Agencies
• Conservation NGOs
• Research & Academic Institutes
• Zoos & Aquaria
• Others
By Region:
North America
• U.S.
• Canada
Europe
• UK
• Germany
• France
• Spain
• Italy
• ROE
Asia Pacific
• China
• India
• Japan
• Australia
• South Korea
• RoAPAC
Latin America
• Brazil
• Mexico
Middle East & Africa
• Saudi Arabia
• South Africa
• RoMEA
Years considered for the study are as follows:
• Historical year – 2022
• Base year – 2023
• Forecast period – 2024 to 2032
Key Takeaways:
• Market Estimates & Forecast for 10 years from 2022 to 2032.
• Annualized revenues and regional level analysis for each market segment.
• Detailed analysis of geographical landscape with Country level analysis of major regions.
• Competitive landscape with information on major players in the market.
• Analysis of key business strategies and recommendations on future market approach.
• Analysis of competitive structure of the market.
• Demand side and supply side analysis of the market.

ページTOPに戻る

Table of Contents

Table of Contents
Chapter 1. Global Wildlife Health Market Executive Summary
1.1. Global Wildlife Health Market Size & Forecast (2022–2032)
1.2. Regional Summary
1.3. Segmental Summary
1.3.1. By Species
1.3.2. By Products & Services
1.3.3. By End-user
1.4. Key Trends
1.5. Recession Impact
1.6. Analyst Recommendation & Conclusion
Chapter 2. Global Wildlife Health Market Definition and Research Assumptions
2.1. Research Objective
2.2. Market Definition
2.3. Research Assumptions
2.3.1. Inclusion & Exclusion
2.3.2. Limitations
2.3.3. Supply Side Analysis
2.3.3.1. Availability
2.3.3.2. Infrastructure
2.3.3.3. Regulatory Environment
2.3.3.4. Market Competition
2.3.3.5. Economic Viability (Buyer’s Perspective)
2.3.4. Demand Side Analysis
2.3.4.1. Regulatory Frameworks
2.3.4.2. Technological Advancements
2.3.4.3. Environmental Considerations
2.3.4.4. Stakeholder Awareness & Acceptance
2.4. Estimation Methodology
2.5. Years Considered for the Study
2.6. Currency Conversion Rates
Chapter 3. Global Wildlife Health Market Dynamics
3.1. Market Drivers
3.1.1. Expansion of One Health Initiatives
3.1.2. Rising Zoonotic Disease Surveillance
3.1.3. Escalating Biodiversity Conservation Funding
3.2. Market Challenges
3.2.1. Logistical Complexities in Remote Environments
3.2.2. High Cost of Species-Specific Solutions
3.3. Market Opportunities
3.3.1. Integration of AI and GIS for Disease Tracking
3.3.2. Development of Portable Diagnostic Platforms
3.3.3. Growth in Public–Private Conservation Partnerships
Chapter 4. Global Wildlife Health Market Industry Analysis
4.1. Porter’s Five Forces Model
4.1.1. Bargaining Power of Suppliers
4.1.2. Bargaining Power of Buyers
4.1.3. Threat of New Entrants
4.1.4. Threat of Substitutes
4.1.5. Competitive Rivalry
4.1.6. Futuristic Approach to Porter’s Model
4.1.7. Porter’s Impact Analysis
4.2. PESTEL Analysis
4.2.1. Political
4.2.2. Economic
4.2.3. Social
4.2.4. Technological
4.2.5. Environmental
4.2.6. Legal
4.3. Top Investment Opportunities
4.4. Top Winning Strategies
4.5. Disruptive Trends
4.6. Industry Expert Perspectives
4.7. Analyst Recommendation & Conclusion
Chapter 5. Global Wildlife Health Market Size & Forecasts by Species 2022–2032
5.1. Segment Dashboard
5.2. Global Market: Species Revenue Trend Analysis, 2022 & 2032 (USD Million)
5.2.1. Mammals
5.2.2. Birds
5.2.3. Fish
5.2.4. Reptiles
5.2.5. Amphibians
Chapter 6. Global Wildlife Health Market Size & Forecasts by Products & Services 2022–2032
6.1. Segment Dashboard
6.2. Global Market: Products & Services Revenue Trend Analysis, 2022 & 2032 (USD Million)
6.2.1. Pharmaceuticals – Drugs
6.2.2. Pharmaceuticals – Vaccines
6.2.3. Medical Devices – Diagnostics Equipment
6.2.4. Medical Devices – Consumables
6.2.5. Veterinary Services
Chapter 7. Global Wildlife Health Market Size & Forecasts by End-user 2022–2032
7.1. Segment Dashboard
7.2. Global Market: End-user Revenue Trend Analysis, 2022 & 2032 (USD Million)
7.2.1. Government & Wildlife Agencies
7.2.2. Conservation NGOs
7.2.3. Research & Academic Institutes
7.2.4. Zoos & Aquaria
7.2.5. Others
Chapter 8. Global Wildlife Health Market Size & Forecasts by Region 2022–2032
8.1. North America
8.1.1. U.S. Market
8.1.1.1. Species breakdown size & forecasts, 2022–2032
8.1.1.2. Products & Services breakdown size & forecasts, 2022–2032
8.1.2. Canada Market
8.2. Europe
8.2.1. UK Market
8.2.2. Germany Market
8.2.3. France Market
8.2.4. Spain Market
8.2.5. Italy Market
8.2.6. Rest of Europe Market
8.3. Asia Pacific
8.3.1. China Market
8.3.2. India Market
8.3.3. Japan Market
8.3.4. Australia Market
8.3.5. South Korea Market
8.3.6. Rest of APAC Market
8.4. Latin America
8.4.1. Brazil Market
8.4.2. Mexico Market
8.5. Middle East & Africa
8.5.1. Saudi Arabia Market
8.5.2. South Africa Market
8.5.3. Rest of MEA Market
Chapter 9. Competitive Intelligence
9.1. Key Company SWOT Analysis
9.1.1. Zoetis Inc.
9.1.2. Merck & Co., Inc.
9.1.3. Virbac
9.2. Top Market Strategies
9.3. Company Profiles
9.3.1. Zoetis Inc.
9.3.1.1. Key Information
9.3.1.2. Overview
9.3.1.3. Financial (Subject to Data Availability)
9.3.1.4. Product Summary
9.3.1.5. Market Strategies
9.3.2. Merck & Co., Inc.
9.3.3. Virbac
9.3.4. Boehringer Ingelheim International GmbH
9.3.5. Ceva Santé Animale
9.3.6. Elanco Animal Health Incorporated
9.3.7. IDEXX Laboratories, Inc.
9.3.8. Vetoquinol SA
9.3.9. Thermo Fisher Scientific Inc.
9.3.10. Biovet S.A.
9.3.11. Hester Biosciences Limited
9.3.12. Phibro Animal Health Corporation
9.3.13. Indian Immunologicals Ltd
9.3.14. Neogen Corporation
9.3.15. Bimeda Inc.
Chapter 10. Research Process
10.1. Research Process
10.1.1. Data Mining
10.1.2. Analysis
10.1.3. Market Estimation
10.1.4. Validation
10.1.5. Publishing
10.2. Research Attributes